ID   MEL114433
AC   CVCL_B0CE
SY   Mel114433; Melanoma model 1; M1
DR   ATCC; CRL-3473
DR   GEO; GSM4301282
DR   Wikidata; Q108820900
RX   PubMed=32284588;
CC   Doubling time: ~24 hours (ATCC=CRL-3473).
CC   Transformant: NCIt; C17231; Ultraviolet radiation.
CC   Omics: Genomics; Whole exome sequencing.
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
CC   Breed/subspecies: C57BL/6 BrafCA/+, Ptenflox/+, Cdkn2aflox/+, Tyr-CreERT2-tg.
DI   NCIt; C21790; Mouse melanoma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
SX   Female
AG   Adult
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 10-04-25; Version: 6
//
RX   PubMed=32284588; DOI=10.1038/s41591-020-0818-3; PMCID=PMC8482620;
RA   Perez-Guijarro E., Yang H.H., Araya R.E., El Meskini R., Michael H.T.,
RA   Vodnala S.K., Marie K.L., Smith C., Chin S., Lam K.C., Thorkelsson A.,
RA   Iacovelli A.J., Kulaga A., Fon A.-Y., Michalowski A.M., Hugo W.,
RA   Lo R.S., Restifo N.P., Sharan S.K., Van Dyke T., Goldszmid R.S.,
RA   Ohler Z.W., Lee M.P., Day C.-P., Merlino G.T.;
RT   "Multimodel preclinical platform predicts clinical response of
RT   melanoma to immunotherapy.";
RL   Nat. Med. 26:781-791(2020).
//